A Phase 1 interventional study of MEN2312 and Elacestrant in Advanced Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Recruiting at 47 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Breast Neoplasms by Menarini Group — 4 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Menarini Group.
Among the 14 studies in Breast Neoplasms by Menarini Group, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 12th registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →4 of the 14 studies in Breast Neoplasms by Menarini Group are open now, in 11 countries. Recruiting first, the newest first:
Stemline Therapeutics, Inc. · Sites in Japan
Ages 18+
Menarini Silicon Biosystems, INC · Sites in United States
Ages 18+
Stemline Therapeutics, Inc. · Sites in United States, Belgium, France and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 2
First in 2015; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Median enrollment 66 across the 12 interventional studies, 126 across the 2 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Stemline Therapeutics, Inc., one of the names counted as Menarini Group. Under that name alone:
Stemline Therapeutics, Inc. is the lead sponsor of 23 studies on the registry; 7 are open to participants now.
4 of the studies in Breast Neoplasms by Menarini Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05596409Stemline Therapeutics, Inc.ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | 2026-11 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT05563220Stemline Therapeutics, Inc.Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | 2026-12-27 |
| NCT06638307Stemline Therapeutics, Inc.A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | 2027-10-24 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Breast Neoplasms by Menarini Group, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MEN2312.
Drug: MEN2312
Participants will receive MEN2312 in combination with elacestrant.
Drug: MEN2312 · Drug: Elacestrant
MEN2312 administered as oral tablets.
Elacestrant administered as oral tablets.
Also known as: Orserdu
Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
Time frame: Baseline through Day 28
Recommended Phase 2 Dose (RP2D) of MEN2312
Time frame: Baseline through Month 6
Overall Response Rate (ORR)
Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)
Duration of Response (DOR)
Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)
Clinical Benefit Rate (CBR)
Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)
Progression-free Survival (PFS)
Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)
Overall Survival (OS)
Time frame: Baseline through 3 months after the last treatment administration (up to approximately 9 months)
Time to Response (TTR)
Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)
Area Under the Plasma Concentration-time Curve (AUC) of MEN2312 When Administered as Monotherapy
Time frame: Up to 6 months post dose
AUC of MEN2312 When Administered as Combination Therapy
Time frame: Up to 6 months post dose
Amount of MEN2312 Excreted in Urine When Administered as Monotherapy
Time frame: Up to 2 months post dose
Comparison of Plasma Concentration of MEN2312 Monotherapy With MEN2312 Combination Therapy
Time frame: Up to 6 months post dose
Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 35 months is below that.
Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.